RECURSION PHARMACEUTICALS, INC. (RXRX) Form 8-K — Oct 15, 2026
$RXRXForm 8-KItems 1.01, 2.02, 7.01, 8.01, 9.01Filed Oct 15, 2026, 8:46 AM ET0001601830-26-000128Original filing
Recursion Pharmaceuticals priced a public offering of 61,540,000 Class A shares at $3.25 per share on October 15, 2026, for expected gross proceeds of roughly $200 million, led by Leerink, Goldman Sachs, Morgan Stanley and Evercore. The deal closes October 16 with a 45-day lock-up on insiders and the company. The company also disclosed preliminary Q3 cash of approximately $561 million, including $86 million of net ATM proceeds, and said existing cash plus offering proceeds will fund operations into 2029.
Key figures
- Cash Position
- 561000000
- Gross Proceeds
- 200000000
- Offering Price
- 3.25
- Shares Offered
- 61540000
- Cash runway
- into 2029
- Lockup days
- 45
- Atm shares sold
- 23696330
- Atm net proceeds q3
- 86000000
- Fap addressable market
- 15000000000
- Sanofi option milestone
- 10000000
- Sanofi additional milestones
- 300000000
- Sanofi total payments to date
- 144000000
- Rec4881 median polyp reduction pct
- 47
- Rec1245 disease control 45 65mg pct
- 91.7
- Underwriter purchase price per share
- 3.055
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.